首页> 外文期刊>Recent Patents on Inflammation & Allergy Drug Discovery >The Situation of Chemokine Ligands and Receptors Gene Expression, Following the Oral Administration of Drug Mannuronic Acid in Rheumatoid Arthritis Patients
【24h】

The Situation of Chemokine Ligands and Receptors Gene Expression, Following the Oral Administration of Drug Mannuronic Acid in Rheumatoid Arthritis Patients

机译:趋化因子配体和受体基因表达的情况,后者在类风湿性关节炎患者中口服施用药物甘露糖酸

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Background: Regarding the leukocytes infiltration into the synovium of Rheumatoid Arthritis (RA) patients is mostly mediated by chemokine ligands and receptors, and following the efficient and motivating results of international Phase III clinical trial of beta-D-Mannuronic acid (M2000) patented EP067919 (2017), as a novel anti-inflammatory drug, in patients with RA, the present research was designed.
机译:背景:关于风湿性关节炎(RA)患者的白细胞浸润主要由趋化因子配体和受体介导,以及β-D-甘露糖酸(M2000)专利EP067919的国际期III临床试验的有效和激励结果。 (2017),作为一种新型的抗炎药,在RA患者中,设计了本研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号